We provide comprehensive genome analysis for newborns to predict long-term genetic diseases. By identifying markers for diabetes, thalassemia, and more, we empower families to take early, life-saving precautions.
By synthesizing a newborn's genomic data shortly after birth, our models calculate risk indices for inheritable conditions, enabling proactive, rather than reactive, healthcare throughout their life.
Non-invasive extraction of DNA samples for comprehensive mapping right after birth.
Scanning for specific genetic markers tied to diabetes, thalassemia, and inherited disorders.
Partnering with clinicians to build lifelong health and dietary plans to mitigate risks.
Each Novo Aetas program is designed around traceable data handling, reviewable outputs, and clear next steps for the teams responsible for acting on the results.
A structured intake process to confirm sample type, goals, constraints and decision criteria before analysis begins.
Access-controlled workflows for sensitive genomic, molecular, agricultural and partner operating data.
Plain-language summaries, technical detail and practical recommendations tailored to the project context.
A final walkthrough with stakeholders so findings are understood before pilots, care planning or deployment.
Discover the power of Novo Aetas biotech infrastructure today. Let's build the future together.